Edesa and the Government of Canada amended a contribution agreement worth up to CAD $23 million ($17 million USD) in partially repayable funding. Repayment would begin only if the company earns gross revenue.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $10.3 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Edesa Biotech
Has Edesa Biotech raised money recently?
Our latest story on this, dated Feb 13, 2025: "Edesa Biotech closes $15.0 million private placement led by Velan Capital". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Edesa Biotech?
Edesa Biotech, Inc. trades under the ticker EDSA on NASDAQ.
Where is Edesa Biotech listed?
Edesa Biotech, Inc. is listed on NASDAQ.
What is the SEC CIK of Edesa Biotech?
The SEC Central Index Key (CIK) for Edesa Biotech, Inc. is 1540159. Its filings are on SEC EDGAR.
How many shares does Edesa Biotech have outstanding?
9,641,031 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Edesa Biotech listed under?
Our directory records Edesa Biotech, Inc. under Canada.
What does Edesa Biotech do?
Our directory classifies Edesa Biotech, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Edesa Biotech?
The ISIN recorded for Edesa Biotech, Inc. is CA27966L3065.
Does aibio.space cover Edesa Biotech?
aibio.space lists Edesa Biotech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Edesa Biotech incorporated?
SEC records list its state or country of incorporation as A1.
Is Edesa Biotech profitable?
Edesa Biotech, Inc. reported a net loss of $7.2 million for the fiscal year ended Sep 30, 2025, and used $7.3 million of cash in operations, per its annual report to the SEC.
How much does Edesa Biotech spend on research and development?
$3.7 million in the fiscal year ended Sep 30, 2025, per its annual report.
How much cash does Edesa Biotech have?
$10.3 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Edesa Biotech (EDSA) stock news?
Our latest story on Edesa Biotech, dated Sep 30, 2025: "Edesa Biotech amends Canada funding deal, first repayment moves to 2032". Edesa and the Government of Canada amended a contribution agreement worth up to CAD $23 million ($17 million USD) in partially repayable funding. Repayment would begin only if the company earns gross revenue. Source.
How long will Edesa Biotech's cash last?
From our story of Sep 30, 2025: The company's 2024 annual report, filed December 13, 2024, carried a going concern warning. Source.
Investor discussion: Edesa Biotech
Members talk about Edesa Biotech (EDSA). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Edesa Biotech, newest first. Each line links the filing it comes from.
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.02,5.03,8.01,9.01). Source
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,3.03,5.03,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:EDSA on TradingView.
SEC filings and registration
SEC name
Edesa Biotech, Inc.
CIK
1540159
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
EDSA (Nasdaq)
State or country of incorporation
A1
Fiscal year ends
September 30
Filer category
Non-accelerated filer<br>Smaller reporting company
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Edesa Biotech, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EDSA, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio